Infarkt miokarda u zhenshchin s izbytochnoy massoy tela i ozhireniem
- Authors: Kislyak O.A1, Starodubova A.V1, Khautieva F.M1, Kopelev A.A1
-
Affiliations:
- Российский государственный медицинский университет им. Н.И.Пирогова, Москва
- Issue: Vol 12, No 10 (2010)
- Pages: 26-31
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/93209
- ID: 93209
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O. A Kislyak
Российский государственный медицинский университет им. Н.И.Пирогова, Москва
A. V Starodubova
Российский государственный медицинский университет им. Н.И.Пирогова, Москва
F. M Khautieva
Российский государственный медицинский университет им. Н.И.Пирогова, Москва
A. A Kopelev
Российский государственный медицинский университет им. Н.И.Пирогова, Москва
References
- Bello N, Mosca L. Epidemiology of Coronary heart disease in Women. Progr Cardiovasc Dis 2004; 46: 287–95.
- Терещенко С.Н., Ускач Т.М., Косицина И.В.и др. Особенности сердечно - сосудистых заболеваний и их лечение у женщин. Кардиология. 2005; 1: 98–102.
- Green L.A, Ruffin V.T. Differences in management of suspected myocardial infarction in men and women. J Fam Pract 1993; 36: 389–93.
- Simon T, Mary-Krause M, Cambou J.P et al. Impact of age and gender on in - hospital and late mortality after acute myocardial infarction: increased early risk in younger women: results from the French nation - wide USIC registries. Eur Heart J 2006; 27: 1282–8.
- Hunt K.J, Resendez R.G, Williams K et al. National cholesterol education program versus World Health Organization metabolic syndrome in relation to all - cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–7.
- Diabetes, Pre - diabetes and Cardiovascular diseases. 2007. Task Force. Eur Heart J 2007; 9 (Suppl. C): 1–74.
- Мамедов М.Н. Нарушение толерантностик глюкозе: кто и как должен лечить? Кардиоваск. тер.и профилак. 2005; 4 (6): 89–96.
- Chiasson J-L, Josse R.G, Gomis R et al. Acarbose treatment and the risk od cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 2003; 290: 486–94.
- Labrid C. Cellular disorders induced by ischemia. The effect of trimetazidine. Presse Med 1986; 15: 1754–7.
- Kantor P.F, Lucien A, Kozak R et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long - chain 3-ketoacyl coenzyme A thiolase. J Circ Res 2000; 86: 580–8.
- Effect of 48-h intravenous trimetazidine on shortand long - term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double - blind, placebo - controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Eur Heart J 2000; 21: 1537–46.
- Iyengar S.S, Rosano G. Effect of antianginal drugs in stable angina jn predicted mortality risk after survivinga myocardial infarction. Am J Cardiovasc Drugs 2009; 9: 293–7.
- Ulgen M.S, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal - averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol 2001; 77: 255–62.
- Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiologic interpretation, and clinical use. Circulation 1996; 93: 1043.
- Lopaschuk G.D. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12 (Suppl. 1): S8–11.
- Лупанов В.П. Триметазидин МВ у больныхс ишемической болезнью сердца (обзор). Cons. Med. 2010; 1: 5–11.
Supplementary files
